NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016

David S. Ettinger; Douglas E. Wood; Wallace Akerley; Lyudmila A. Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T. Cheney; Lucian R. Chirieac; Thomas A. D'amico; Thomas Dilling; Michael Dobelbower; Ramaswamy Govindan; Mark Hennon; Leora Horn; Thierry M. Jahan; Ritsuko Komaki; Rudy P. Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W. Loo; Renato Martins; Gregory A. Otterson; Jyoti D. Patel; Katherine M. Pisters; Karen Reckamp; Gregory J. Riely; Steven E. Schild; Theresa A. Shapiro; Neelesh Sharma; Scott J. Swanson; James Stevenson; Kurt Tauer; Stephen C. Yang; Kristina Gregory; Miranda Hughes

doi:10.6004/jnccn.2016.0087

NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016

David S. Ettinger
, Douglas E. Wood
, Wallace Akerley
, Lyudmila A. Bazhenova
, Hossein Borghaei
, David Ross Camidge
, Richard T. Cheney
, Lucian R. Chirieac
, Thomas A. D'amico
, Thomas Dilling
, Michael Dobelbower
, Ramaswamy Govindan
, Mark Hennon
, Leora Horn
, Thierry M. Jahan
, Ritsuko Komaki
, Rudy P. Lackner
, Michael Lanuti
, Rogerio Lilenbaum
, Jules Lin

Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes

Johns Hopkins University
Seattle Cancer Care Alliance
University of Utah
University of California at San Diego
University of Colorado Anschutz Medical Campus
Roswell Park Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center
Duke University
Moffitt Cancer Center
University of Alabama at Birmingham
Washington University St. Louis
Vanderbilt University
University of California at San Francisco
University of Texas MD Anderson Cancer Center
University of Nebraska Medical Center
Massachusetts General Hospital Cancer Center
Yale University
University of Michigan, Ann Arbor
Stanford University
Ohio State University
Northwestern University
City of Hope National Medical Center
Memorial Sloan-Kettering Cancer Center
Mayo Clinic
Case Western Reserve University
University of Tennessee Health Science Center
National Comprehensive Cancer Network

Research output: Contribution to journal › Review article › peer-review

92 Scopus citations

Abstract

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Original language	English
Pages (from-to)	825-836
Number of pages	12
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	14
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2016.0087
State	Published - Jul 1 2016

Access to Document

10.6004/jnccn.2016.0087

Cite this

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'amico, T. A., Dilling, T., Dobelbower, M., Govindan, R., Hennon, M., Horn, L., Jahan, T. M., Komaki, R., Lackner, R. P., Lanuti, M., Lilenbaum, R., ... Hughes, M. (2016). NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016. JNCCN Journal of the National Comprehensive Cancer Network, 14(7), 825-836. https://doi.org/10.6004/jnccn.2016.0087

@article{afcab62f863244febac23e71c37a3c8f,

title = "NCCN Guidelines{\textregistered}: Insights malignant pleural mesothelioma, version 3.2016",

abstract = "These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.",

author = "Ettinger, \{David S.\} and Wood, \{Douglas E.\} and Wallace Akerley and Bazhenova, \{Lyudmila A.\} and Hossein Borghaei and Camidge, \{David Ross\} and Cheney, \{Richard T.\} and Chirieac, \{Lucian R.\} and D'amico, \{Thomas A.\} and Thomas Dilling and Michael Dobelbower and Ramaswamy Govindan and Mark Hennon and Leora Horn and Jahan, \{Thierry M.\} and Ritsuko Komaki and Lackner, \{Rudy P.\} and Michael Lanuti and Rogerio Lilenbaum and Jules Lin and Loo, \{Billy W.\} and Renato Martins and Otterson, \{Gregory A.\} and Patel, \{Jyoti D.\} and Pisters, \{Katherine M.\} and Karen Reckamp and Riely, \{Gregory J.\} and Schild, \{Steven E.\} and Shapiro, \{Theresa A.\} and Neelesh Sharma and Swanson, \{Scott J.\} and James Stevenson and Kurt Tauer and Yang, \{Stephen C.\} and Kristina Gregory and Miranda Hughes",

note = "Publisher Copyright: {\textcopyright} JNCCN - Journal of the National Comprehensive Cancer Network.",

year = "2016",

month = jul,

day = "1",

doi = "10.6004/jnccn.2016.0087",

language = "English",

volume = "14",

pages = "825--836",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "7",

}

Ettinger, DS, Wood, DE, Akerley, W, Bazhenova, LA, Borghaei, H, Camidge, DR, Cheney, RT, Chirieac, LR, D'amico, TA, Dilling, T, Dobelbower, M, Govindan, R, Hennon, M, Horn, L, Jahan, TM, Komaki, R, Lackner, RP, Lanuti, M, Lilenbaum, R, Lin, J, Loo, BW, Martins, R, Otterson, GA, Patel, JD, Pisters, KM, Reckamp, K, Riely, GJ, Schild, SE, Shapiro, TA, Sharma, N, Swanson, SJ, Stevenson, J, Tauer, K, Yang, SC, Gregory, K & Hughes, M 2016, 'NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 7, pp. 825-836. https://doi.org/10.6004/jnccn.2016.0087

TY - JOUR

T1 - NCCN Guidelines®

T2 - Insights malignant pleural mesothelioma, version 3.2016

AU - Ettinger, David S.

AU - Wood, Douglas E.

AU - Akerley, Wallace

AU - Bazhenova, Lyudmila A.

AU - Borghaei, Hossein

AU - Camidge, David Ross

AU - Cheney, Richard T.

AU - Chirieac, Lucian R.

AU - D'amico, Thomas A.

AU - Dilling, Thomas

AU - Dobelbower, Michael

AU - Govindan, Ramaswamy

AU - Hennon, Mark

AU - Horn, Leora

AU - Jahan, Thierry M.

AU - Komaki, Ritsuko

AU - Lackner, Rudy P.

AU - Lanuti, Michael

AU - Lilenbaum, Rogerio

AU - Lin, Jules

AU - Loo, Billy W.

AU - Martins, Renato

AU - Otterson, Gregory A.

AU - Patel, Jyoti D.

AU - Pisters, Katherine M.

AU - Reckamp, Karen

AU - Riely, Gregory J.

AU - Schild, Steven E.

AU - Shapiro, Theresa A.

AU - Sharma, Neelesh

AU - Swanson, Scott J.

AU - Stevenson, James

AU - Tauer, Kurt

AU - Yang, Stephen C.

AU - Gregory, Kristina

AU - Hughes, Miranda

PY - 2016/7/1

Y1 - 2016/7/1

N2 - These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

AB - These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

UR - https://www.scopus.com/pages/publications/84978806340

U2 - 10.6004/jnccn.2016.0087

DO - 10.6004/jnccn.2016.0087

M3 - Review article

C2 - 27407123

SN - 1540-1405

VL - 14

SP - 825

EP - 836

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 7

ER -

NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016

Abstract

Access to Document

Other files and links

Fingerprint

Cite this